The long-term goal of this project is to increase the cure rate of primary liver cancer by adapting treatment to the individual patient response. This goal will be carried out through two specific aims.
Aim 1 is to complete a phase II clinical trial for patients with HCC in which the dose is based on the individual patient's liver function. We will measure global and regional changes in liver function in patients undergoing radiation therapy for HCC who are ineligible for or have progressed after standard therapy. We will administer 60% of the treatment, wait the month that we have shown is required to express early liver injury, reassess tumor response, liver function, and liver injury to adapt the dose for the rest of treatment, based on a more accurate estimate of that individual patient's risk of toxicity. We will also assess regional response in the tumor. We hypothesize that adapting radiation therapy based on the tumor and uninvolved liver responses assessed during treatment will permit us to achieve a >80% 1 year tumor control rate while causing no greater toxicity than standard therapy.
Aim 2 is to conduct a phase II randomized trial to compare standard therapy (fixed course treatment without adaptation) to the model proposed in Aim 1 that adapts therapy based on the individual patient's response.
Aim 1 will provide the data to Project 4 to help develop a model for treatment that is predicted to maximize tumor response by intensifying treatment to refractory subvolumes of tumor (defined by Project 3), and minimize uninvolved liver injuty by delivering dose through non-functioning regions of the liver, and by knowing the radiation sensitivity of the individual patient. This will be accomplished by replanning treatment after 60% has been delivered based on tumor response and uninvolved liver injury. This arm will be compared in a randomized phase 11 trial to a standard arm using an approach that bases the dose on the volume of uninvolved liver spared (which we developed in an earlier version of this PO-1), but adapts neither tumor nor uninvolved liver dose and dose distribution. We hypothesize that treating patients with adaptive radiation therapy based on the tumor and uninvolved liver responses assessed during treatment will produce superior tumor control at no greater toxicity than the standard arm that gives a fixed dose based on the volume of uninvolved liver irradiated (but does not adapt therapy). The impact of this work is that it will develop a new paradigm for radiation oncology in which treatment is optimized by adapting therapy to the individual patient response, rather than based on the """"""""average patient"""""""".

Public Health Relevance

Radiation therapy alone cures only a small fraction of patients with unresectable liver cancer. We propose to improve the cure rate by adapting therapy to the individual patient by assessing midtreatment changes in the patient's tumor and normal tissues. These changes will reveal to us the individual patient's sensitivity to treatment so that we can give more radiation to the aggressive regions of the tumor while avoiding normal functioning liver. Our approach should be vastly superior to basing all treatment on the average patient.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Ohri, Nitin; Tomé, Wolfgang A; Méndez Romero, Alejandra et al. (2018) Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys :
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Wang, Shulian; Campbell, Jeff; Stenmark, Matthew H et al. (2018) A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiother Oncol 126:506-510
Sapir, Eli; Tao, Yebin; Schipper, Matthew J et al. (2018) Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:122-130
Hawkins, Peter G; Boonstra, Philip S; Hobson, Stephen T et al. (2018) Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Transl Oncol 11:102-108
Sun, Yilun; Hawkins, Peter G; Bi, Nan et al. (2018) Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 100:107-114
Kong, Feng-Ming Spring; Li, Ling; Wang, Weili et al. (2018) Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol :
Shilkrut, Mark; Sapir, Eli; Hanasoge, Sheela et al. (2018) Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol 41:326-331
Jackson, William C; Tao, Yebin; Mendiratta-Lala, Mishal et al. (2018) Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys 100:950-958
Miften, Moyed; Vinogradskiy, Yevgeniy; Moiseenko, Vitali et al. (2018) Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 289 publications